Hologic, Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 6,902 shares of the stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the sale, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Elaine Ullian also recently made the following trade(s):

  • On Monday, July 3rd, Elaine Ullian sold 8,849 shares of Hologic stock. The stock was sold at an average price of $45.28, for a total transaction of $400,682.72.
  • On Friday, June 2nd, Elaine Ullian sold 8,938 shares of Hologic stock. The stock was sold at an average price of $43.99, for a total transaction of $393,182.62.

Hologic, Inc. (NASDAQ HOLX) traded down 0.56% on Monday, reaching $39.03. 4,007,627 shares of the company’s stock were exchanged. The stock has a market capitalization of $10.95 billion, a PE ratio of 14.54 and a beta of 0.90. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80. The firm has a 50 day moving average of $45.06 and a 200 day moving average of $42.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. During the same quarter last year, the firm posted $0.51 earnings per share. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Equities analysts predict that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Hologic, Inc. (HOLX) Director Sells $276,908.24 in Stock” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/07/hologic-inc-holx-director-sells-276908-24-in-stock.html.

Several research firms have recently issued reports on HOLX. Royal Bank Of Canada dropped their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research report on Thursday. Deutsche Bank AG dropped their price objective on shares of Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday. Jefferies Group LLC set a $49.00 price objective on shares of Hologic and gave the stock a “buy” rating in a research report on Sunday, May 28th. Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. Finally, BidaskClub lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $48.64.

Several large investors have recently made changes to their positions in the company. Victory Capital Management Inc. increased its stake in shares of Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares during the last quarter. Columbus Circle Investors bought a new stake in shares of Hologic during the second quarter valued at about $54,511,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock valued at $48,100,000 after buying an additional 738,215 shares during the last quarter. Institutional investors and hedge funds own 94.46% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.